May 26, 2017 Columns by John Connor Lemtrada I: This Island Couch The latest drug media storm to erupt in Britain is “Spice,” which causes users to become living statues. Exactly a year ago, I became a living statue for six weeks, and not one reporter hassled me. That would have broken the monotony! We all have our own version…
April 28, 2017 News by Patricia Silva, PhD Lemtrada Might Outperform Ocrevus in Preventing MS Relapses, Italian Researchers Say Lemtrada (alemtuzumab) may be more effective in preventing relapses in multiple sclerosis patients than the newly approved Ocrevus (ocrelizumab), according to a study presented April 28 at the American Academy of Neurology (AAN) 2017 Annual Meeting in Boston. The study, supported by Sanofi Genzyme and Bayer HealthCare Pharmaceuticals, compared…
April 26, 2017 News by Joana Fernandes, PhD Sanofi Genzyme to Present New Data on MS Treatments Lemtrada and Aubagio Sanofi Genzyme will present new results on follow-up studies of its products Lemtrada (alemtuzumab) and Aubagio (teriflunomide), both of which have been approved for the treatment of relapsing-remitting multiple sclerosis (RRMS). The new data will be presented at the American Academy of Neurology (AAN) Annual Meeting taking…
April 20, 2017 News by Patricia Silva, PhD AAN Annual Meeting Offers First Ocrevus Data Update Since MS Therapy’s Approval by FDA New data on the recently approved multiple sclerosis (MS) drug Ocrevus (ocrelizumab) will be presented at the upcoming American Academy of Neurology (AAN) Annual Meeting 2017, which will take place April 22-28 in Boston. The meeting is the first scientific conference focusing on neurology since the U.S.
April 19, 2017 News by Patricia Inacio, PhD Sanofi Genzyme to Discuss Three Multiple Sclerosis Therapies at Boston Event Sanofi Genzyme will discuss three of its multiple sclerosis therapies at the American Academy of Neurology annual meeting in Boston, April 22-28. The presentations will cover two approved treatments for relapsing MS – Lemtrada (alemtuzumab) and Aubagio (teriflunomide) – and one that has been in a Phase 1 clinical…
March 28, 2017 Columns by Ed Tobias My MS Is Getting to Be a Pain, Literally For most of the 36 years since I was diagnosed with multiple sclerosis I’ve not been bothered by pain. Just lucky, I guess. Until last month. Suddenly, I’ve developed pain in both hips and I don’t know why. The pain is most intense when I first put my feet on…
February 23, 2017 News by Patricia Inacio, PhD #ACTRIMS2017 – Lemtrada Maintains Durable Positive Effects in MS Without Additional Treatment Two Phase 3 clinical trials investigating the long-term effects of Lemtrada (alemtuzumab) in multiple sclerosis (MS) patients showed the drug maintained improved outcomes, even in the absence of further treatment. Both studies were presented at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2017 Forum, held…
February 6, 2017 News by Özge Özkaya, PhD Switching From Gilenya to Lemtrada Seen to Trigger Disease Activity in Some MS Patients Switching from Gilenya (fingolimod) to Lemtrada (alemtuzumab) triggers significant and unexpected disease activity in some patients with multiple sclerosis (MS), according to a study published in the scientific journal Neurology Neuroimmunology and Neuroinflammation.
January 27, 2017 Columns by Ed Tobias My Lemtrada Coaster Has Been Rolling About two weeks ago I wrote about my roller-coaster ride being pretty smooth since my first round of Lemtrada infusions ended in early December. Well, the loops are now looping. Month two post-infusion began with a good lab report, but also with an appearance of the up-down fatigue monster.
